Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 2, 2005, Pages 143-149

  Wiedeman, Paul E ^a   Trevillyan, James M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GSK 23A; INSULIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ALOPECIA; ANEMIA; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DEATH; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; METABOLIC SYNDROME X; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 22244482444     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.05.020     Document Type: Review

References (43)

1. S. Mojsov et al. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas J. Clin. Invest. 79 1987 616-619
2. B. Kreymann et al. Glucagon-like peptide-17-36: A physiological incretin in man Lancet 2 1987 1300-1304
3. H.C. Fehmann et al. Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma betaTC-1 cells Endocrinology 130 1992 159-166
4. G. Xu et al. Exendin-4 stimulates both [beta]-cell replication and neogenesis, resulting in increased [beta]-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270-2276
5. G.C. Weir et al. Glucagon-like peptide I (7-37) actions on endocrine pancreas Diabetes 38 1989 338-342
6. H. Larsson et al. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans Acta Physiol. Scand. 160 1997 413-422
7. J. Schirra et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans J. Clin. Invest. 97 1996 92-103
8. A. Wettergren et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Dig. Dis. Sci. 38 1993 665-673
9. M. Zander et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study Lancet 359 2002 824-830
10. M.D. Turton et al. A role for glucagon-like peptide-1 in the central regulation of feeding Nature 379 1996 69-72
11. M.K. Gutniak et al. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes J. Intern. Med. 250 2001 81-87
12. J. Rachman et al. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 40 1997 205-211
13. M. Gutniak et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus N. Engl. J. Med. 326 1992 1316-1322
14. 2 -terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126-1131
15. R. Mentlein et al. Dipeptidyl-peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum Eur. J. Biochem. 214 1993 829-835
16. J.M. Egan et al. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes Am. J. Physiol. 284 2003 E1072-E1079
17. J.J. Meier et al. Gastric inhibitory polypeptide: The neglected incretin revisited Regul. Pept. 107 2002 1-13
18. M.A. Nauck et al. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J. Clin. Invest. 91 1993 301-307
19. F.C. Lynn et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats Diabetes 50 2001 1004-1011
20. R. Mentlein Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul. Pept. 85 1999 9-24
21. D. Marguet et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc. Natl. Acad. Sci. USA 97 2000 6874-6879
22. T. Nagakura et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats Biochem. Biophys. Res. Commun. 284 2001 501-506
23. T. Hansotia et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPPIV inhibitors Diabetes 53 2004 1326-1335
24. S.L. Conarello et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc. Natl. Acad. Sci. USA 100 2003 6825-6830
25. R. Perfetti et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats Endocrinology 141 2000 4600-4605
26. L. Farilla et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats Endocrinology 143 2002 4397-4408
27. J. Zhou et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells Diabetes 48 1999 2358-2366
28. M.K. Reimer et al. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice Eur. J. Endocrinol. 146 2002 717-727
29. J.A. Pospisilik et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 52 2003 741-750
30. A.E. Butler et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 2003 102-110
31. B. Ahrén et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 27 2004 2874-2880
32. G. Lankas et al. Inhibition of DPP8/9 results in toxicity in preclinical species: Potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of type 2 DM Diabetes 53 Suppl. 2 2004 A2(7-OR)
33. D. Kim et al.
34. E.B. Villhauer et al.
35. B. Ahrén et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 2002 869-875
36. E.B. Villhauer et al. 1- 3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 46 2003 2774-2789
37. B. Ahrén et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagons levels in type 2 diabetes J. Clin. Endocrinol. Metab. 89 2004 2078-2084
38. R. Defronzo Effects of Exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Proceedings of the American Diabetes Association 64th Scientific Sessions 4-8 June 2004, Orlando, FL, USA 2004 (abstract 6-LB)
39. J.B. Buse et al. Effects of Exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2004 2628-2635
40. G.A. Herman et al. The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetes Diabetes 53 Suppl. 2 2004 A82 (abstract 353-OR)
41. J.J. Holst et al. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus Curr. Opin. Pharmacol. 4 2004 589-596
42. L.G. Hamann et al. Design, synthesis, and pharmacology of BMS-477118: A long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type II diabetes Proceedings of the 228th American Chemical Society National Meeting 22-26 August 2004, Philadelphia, PA, USA 2004 (abstract MEDI-207)
43. C.D. Haffner et al. Synthesis and biological evaluation of potent, selective, orally active 4-fluoro-2-cyanopyrrolidine inhibitors of DPP-IV Proceedings of the 228th American Chemical Society National Meeting 22-26 August 2004, Philadelphia, PA, USA 2004 (abstract MEDI-205)